It is now accepted that screening for colorectal cancer by faecal occult blood (FOB) testing can reduce disease specific mortality. In the United Kingdom, the studies which have proved most influential are the two population based randomised trials carried out in Nottingham, England and in Funen, Denmark which showed a reduction in deaths from colorectal cancer of 15% and 18% respectively. 1 2 Randomised trials that compare disease specific mortality in populations which have or have not been oVered screening are essential to show the eYcacy of a screening strategy; only by this means can the biases which seem to improve the outcome in screen detected disease be eliminated. 3 However, the results of such trials may not reflect the eVectiveness of screening-that is, they cannot indicate whether or not a screening programme will be feasible when it is introduced as a national programme.
By their nature, randomised trials are tightly controlled studies carried out by highly motivated people, 4 whereas a national service may be subject to variations in levels of enthusiasm and expertise. Furthermore, in population screening, compliance is crucial to success, and the level of compliance obtained by the eVorts of dedicated researchers may be diYcult to replicate in the country at large.
For these reasons, the United Kingdom Government has decided to carry out a 2 year pilot trial to establish whether or not a national colorectal cancer screening programme is feasible. This article describes the process whereby this pilot trial has been established.
Developing the pilot trial
To determine the feasibility of a colorectal screening programme, the National Screening Committee (NSC) held two workshops, one in May 1997 and the second in March 1998. These workshops canvassed a wide range of expert opinion and examined the available evidence. It was concluded that colorectal cancer screening by FOB testing met the NSC criteria for appraising the viability, eVectiveness, and appropriateness of a screening programme based on the 1966 World Health Organisation (WHO) report. 5 However, it was recommended that the feasibility of a national programme should be tested before committing the United Kingdom departments of health to such a programme. To do this, a demonstration pilot based on two resident populations of around 1 million each and comprising one or more health authorities in diVer-ent parts of the country was proposed. It was agreed that the technique should be that used by the Nottingham and Funen trials-that is, biennial FOB testing with colonoscopy as the first line investigation for those who tested positive-and that the pilot would assess the short term outcomes, as defined by the trials, which would indicate whether or not a full scale programme would be likely to reduce mortality at reasonable cost and without undue adverse eVects. It was decided to invite only those between the ages 50 and 69; below this age range disease incidence is low and in those over 70 the uptake may decline. 1 With biennial screening, it was calculated that this would involve inviting about 100 000 people/million of the population every year.
As soon as these proposals had been approved, a letter from the respective NHS management executives was circulated in September 1998 to all health authority and health board general managers and trust chief executives requesting expressions of interest in hosting a pilot site. From the expressions of interest received, five were shortlisted for further consideration by an assessment panel appointed by the National Screening Committee.
Summary points
x Colorectal cancer screening using faecal occult blood (FOB) testing has been proved to reduce disease specific mortality in randomised trials. x Concern that the results of the trials may be diYcult to reproduce in the general population has prompted the United Kingdom Government to carry out a feasibility pilot project. x The pilot trial, which is taking place in Coventry and Warwickshire and in the north-east of Scotland, covers a population of about 2 million. This will involve inviting 400 000 men and women in the 50-69 age range for screening in a 2 year period. x The pilot trial will be assessed on its ability to meet short term outcome goals derived from the results of the randomised trials.
x If a national screening programme is introduced it will present many logistical challenges, including major implications for the provision of colonoscopy, and forward planning will be essential.
The potential sites were then visited by members of this panel and the final selection was made after presentations and interviews. Selection criteria included ability of the applicants to carry out the pilot trial without extra clinical personnel or major capital investment in clinical facilities, but it was agreed that a system for invitation and FOB testing for each pilot site would be centrally funded as would the subsequent investigations. The selection process was completed in February 1999 with the formal announcement that the sites chosen for the pilot were Coventry and Warwickshire (two English health authorities, population around 800 000), and Grampian, Tayside, and Fife (three Scottish health boards, population around 1.2 million). Each of the two pilot sites appointed a clinical director and the first formal appointments funded by the project were two pilot managers, one for each site. An executive group with a remit to oversee the operational development and running of the pilot was then established comprising the national screening coordinators for England and for Scotland, their central project managers, the two clinical directors and the two pilot managers. A United Kingdom steering group was also created to formulate general policy, and this committee comprises representatives from relevant cancer interest groups and professional bodies including the appropriate royal colleges and associations. This organisational structure is described in figure 1 .
For the purposes of developing the pilot trial, working groups were set up to develop the specification for the computer systems, to select the FOB test, to establish two laboratories and central oYces, to develop data sets, protocols, and quality assurance systems for clinical activities, to establish the role of the specialist nurses, and to develop information materials. These groups have finished their preparatory work, which took 12 months, and screening started on 29 March 2000 with the despatch of the first tests.
INFORMATION TECHNOLOGY
A joint specification for the pilot computer systems was drawn up although the software was developed by two separate agencies for the English and Scottish sites. The possibility of one system was explored, but two were needed owing to the diVerent information technology (IT) infrastructures in the two countries. The requirements from these systems comprised the identification of eligible people, invitation of these people for screening, controlling and monitoring their progress through the screening process, recording test results, recording results of subsequent investigations and treatment, and producing performance statistics for operational management, quality assurance, and evaluation. This was a major piece of work and represents a key development central not only to the successful execution of the pilot trial but also to any subsequent national screening programme.
THE TEST
A guaiac based FOB test was selected by means of a European standard competitive bidding process. This test involves the assessment of faecal material from two samples taken from each of three separate stools. Five or six positive squares (strongly positive) are taken as an indication for further investigation, but if one to four squares are positive (weakly positive) the person is invited to repeat the test after appropriate dietary restriction to limit the 2) . Concern was expressed at steering group level that the test selected was not produced by the same manufacturer as that used in the randomised trials. However, a rigorous procurement process had been used and the clinical biochemists involved in the pilot trial were satisfied that the test chosen had identical biochemical specifications to that used in the Nottingham and Funen trials. The choice of test was supported by an independent evaluation commissioned by the Medical Devices Agency, and careful quality management of all aspects of the testing procedure is in place to ensure adequate performance in the screening context.
THE LABORATORY AND CENTRAL OFFICE
Central oYces and laboratories for the two sites have been equipped and staVed to carry out the following functions: (a) to send out the tests and information in the post to the target population identified from computer based population indices; (b) to provide a telephone help line to answer queries from invitees; (c) to receive and process the completed tests; (d) to send out test results; (e) to send out reminders and further test and dietary restriction instructions where appropriate; and (f) to start the required action on receipt of a positive test.
Also, whenever the patients of a particular practice are about to be invited for screening a pilot nurse and the pilot manager visit the practice to explain the purpose and the mechanics of the screening process. Before this u8Figure 2 Flow chart describing the colorectal screening process. 
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Any blue squares visit the practice can be given a list to allow them to identify any patients for whom screening would be inappropriate-for example, patients with an established terminal illness.
NURSE SPECIALISTS
Nurse specialists or "pilot nurses" have a central role in the project. As well as preliminary practice visits, their primary role is to meet people who have had positive tests, to explain the significance of the result and to organise the colonoscopy. At the time of the first meeting the nurse provides a full explanation of the possible benefits and adverse eVects of further investigations, takes a history, makes an appointment for colonoscopy after obtaining fully informed consent, and provides the medication and instructions for bowel preparation.
INFORMATION AND CHOICE
A key component of the pilot trial is to test the feasibility of screening in a climate of increasing awareness and emphasis on fully informed choice. This includes ensuring understanding of the concept of false positive and false negative tests and a clear explanation of the possible adverse eVects. Thus, as well as instructions as to how to carry out the test, it was necessary to develop an invitation that would convey the implications of participating in the screening process and provide a means of communicating positive and negative results that would take the limitations of the FOB test into account. The group charged with this task produced materials that were field tested by an independent market research organisation and modified accordingly.
CLINICAL GROUPS
Working groups on colonoscopy, surgery, radiology, pathology, and nursing have developed common data sets for recording the procedures and the findings. Clear protocols have been developed for all areas and comprehensive quality assurance procedures are in place. EVALUATION Rigorous, independent, evaluation is at the heart of the pilot concept, and this task was put out to tender on behalf of the Health Departments by the research and development division of the English department. On the basis of competitive bids, the evaluation project was awarded to a group from the Universities of Edinburgh, Warwick, and Essex. Apart from examining performance against central benchmarks (table 1) this group will carry out an economic evaluation of the pilot trial, and examine the impact of the programme on primary care and on the provision of secondary care for patients with symptomatic disease requiring gastrointestinal endoscopy. They will also look at compliance, the reasons for non-compliance and the physical and psychological morbidity created by screening. The final report produced by the Evaluation Group will be used as information for the policy advice from the National Screening Committee to Ministers on a national programme.
Challenges for the pilot trial
Screening for cancer is a controversial area, 6 and the introduction of another national screening programme has to be considered very carefully for various reasons. On the positive side, there is good evidence from randomised trials to support the eYcacy of screening for colorectal cancer. 1 2 7 Also, the presence of a screening programme may improve outcomes for reasons other than the screening process itself. For example, during the Nottingham study, the stage of presentation of rectal cancer markedly improved in the control group, presumably because of an educational eVect. 8 It is also of interest that the dramatic drop in breast cancer mortality recently found from registry data from the United Kingdom and the United States 9 coincides with the introduction of widespread screening for the disease. Although this drop cannot be attributed to screening alone, it can be argued that screening and its associated quality assurance has acted as a stimulus for improving both clinical standards and population awareness, leading to earlier presentation and more eVective management.
However, screening trials are carried out by dedicated enthusiasts, and there is a body of opinion which challenges the concept of introducing national programmes on the basis of such trials. Thus, the concept of piloting screening has arisen from a perceived need to show that the short term outcomes achieved by the randomised trials (table 1) can be reproduced in a typical population sample outside the research setting. Apart from this, however, there are other important questions that the pilot trial can answer which will be informative to the final decision about implementation of national screening.
IMPACT ON THE SYMPTOMATIC SERVICE
There is a serious concern that, with diagnostic facilities already stretched, screening may impose an intolerable burden on the health service. 10 Furthermore, it is possible that patients diagnosed with colorectal cancer as a result of screening may receive preferential care by means of speed of access to high quality diagnostic and treatment services. It could be argued that resources allocated to screening would be better used in improving the service for symptomatic patients 11 , and careful costbenefit evaluation of the pilot trial will therefore be essential.
IMPACT ON PRIMARY CARE
A related work load issue is the impact of screening on primary care. Wide consultation with general practitioners (GPs) has shown anxiety that colorectal screening will impose considerable extra work on hard pressed doctors. Practices are given the opportunity to check lists, and if this oVer is taken up, it will involve expenditure of time and eVort. Also, it is inevitable that patients will contact their GPs for advice and information at the various stages of the screening process. The development of the information materials has alleviated this concern, and the central screening oYces oVer telephone help lines which the invitees are encouraged to use rather than contacting their own doctors. Nevertheless, the potential for an increase in the workload of GPs remains and monitoring this is a major component of the evaluation.
It is of interest that previous research by the Nottingham group has shown that screening invitations signed by a GP are more likely to be accepted than those issued by an unfamiliar person or remote authority. 12 However, to minimise the impact on primary care it was decided that the invitation letters should be signed by the lead clinicians of the pilot trial in the first instance. If early analysis of pilot data shows low compliance, it may be necessary to revisit this concept in close consultation with primary care.
FALSE NEGATIVE RESULTS
Increasingly, false negative results in breast and cervical screening are leading to litigation, with patients who develop cancer after a negative test alleging negligence through a delay in diagnosis. 13 The interval cancer rates in the randomised trials indicate that the sensitivity of FOB testing is only in the region of 50% 1 2 , considerably less than that of mammography and cervical cytology. It has therefore been essential for the information materials to make it clear that a negative test, although making the presence of colorectal cancer unlikely, cannot exclude it. A more worrying problem would be the patient who develops a symptomatic cancer shortly after a normal colonoscopy as this could more readily be ascribed to negligence on the part of the endoscopist. However, colonoscopy does miss tumours, even in expert hands, 14 and a quality assurance system for colonoscopy is an important issue for the pilot trial and the evaluators.
FALSE POSITIVE RESULTS
The false positive result is also a source of concern. Quite apart from unnecessary psychological and potential physical morbidity, both of which are subjects of the pilot trial evaluation, many invitees and their GPs may wish to know why the source of the occult blood has not been identified. There are various possibilities. Despite dietary restriction for weakly positive results, diet may be responsible, or there may be unrelated colorectal pathology such as haemorrhoids. Another scenario is a lesion that has been missed at colonoscopy, as outlined above. However, the greatest concern voiced by both GPs and endoscopists during the development of the pilot trial was the possibility of serious upper gastrointestinal pathology. This was considered in the Nottingham screening study, and in a cohort of 283 FOB positive invitees who had no neoplastic disease on colonoscopy only two developed gastric cancer, and both had related symptoms at the time of investigation. 15 Thus, if there are no upper gastrointestinal symptoms, the risk of gastric cancer in FOB positive people is very low.
ACCURACY OF THE TEST
Finally, although eVective, the FOB test is not perfect; it has low sensitivity, and increasing its sensitivity by using diVerent methods of detecting blood lowers its specificity. 16 However, it is the only method of screening that has been shown in randomised controlled trials to reduce mortality from colorectal cancer, and there is no alternative immediately available. Flexible sigmoidoscopy would seem to be considerably more sensitive and specific than FOB testing as it allows around 60% of cancers to be seen, and more proximal cancers tend to be associated with distal polyps, which prompt more extensive colonic investigation. 17 However, the ICRF/MRC trial of once only flexible sigmoidoscopy at age 55-64 is not expected to report analyses to show any eVect on mortality for at least 7 years, 18 and there is some concern about the level of compliance with this test. 19 With all these caveats, it may seem premature even to pilot colorectal cancer screening. However, if the results of the trials can be translated into the general population there is an opportunity to have a positive impact on mortality from colorectal cancer now, and this must be taken seriously. Also, experience from the Nottingham study indicates that there may be important beneficial sequelae; stage at presentation may be improved even in those who do not have their tumours detected by screening 8 and screening may reduce the proportion of tumours presenting as emergencies. 20 Furthermore, estimates of cost per quality adjusted life-year gained from colorectal screening show it to be similar in cost eVectiveness to breast cancer screening in the short term and better in the long term 21 .
Beyond the pilot trial
What can we expect if the pilot is successful, and a national programme of FOB colorectal cancer screening is introduced? Currently, little is known about the volume or quality of colonoscopy available across the country. It has been estimated, from the compliance and positivity rates in the Nottingham study, that about 1200 extra colonoscopies/1 million of the population/year will be required if FOB screening is introduced for the 50-69 age group 1 . It is essential that these colonoscopies are carried out to the highest possible standard to minimise morbidity, missed cancers, and the need for completion barium enemas. The introduction of a national screening programme will pose considerable logistical problems in expanding colonoscopy facilities and training. The pilot sites were chosen on the basis of being able to provide colonoscopy to the required standard, but a national programme will demand substantial but as yet undetermined investment. This can be seen either as a problem or as an opportunity to improve diagnostic services, but, either way, it must not come as a surprise.
About 50% of people with a positive FOB test will have neoplasia, and although 80% of these will only have adenomatous polyps, this has further implications for colonoscopy. Recent evidence from prolonged follow up of the Minnesota randomised trial indicates that FOB screening reduces the incidence of colorectal cancer, presumably as a result of colonoscopic polypectomy. 22 This, combined with evidence in favour of the adenoma-carcinoma sequence 23 , provides a compelling reason to remove screen detected adenomas, but it is not clear what follow up strategy should be used subsequently. Present opinion advocates repeat colonoscopy every 3-5 years, 23 and this would stretch colonoscopy services even further. It may be possible to use a policy of selective endoscopic surveillance on the basis of histological and molecular polyp characteristics, but validation of this approach will require extensive research. In the meantime, although colonoscopic surveillance for people who are diagnosed as having adenomatous polyps does not come under the strict remit of screening, it is essential that this problem is recognised and appropriate facilities put in place before a national programme is set up.
Finally, for reasons already mentioned, the pilot trial has been designed to oVer screening only to those between the ages of 50 and 69, but it is likely that people outside this age range will request screening. This will be carefully monitored during the pilot trial, but if a national programme is instituted research into the benefit of extending the age range in an upward direction will be necessary as potential compliance rates among more elderly people may well have changed in recent years.
The implications of introducing a colorectal cancer screening programme are profound, and, in our view, this new strategy of piloting the process so that a fully informed decision can be made is both responsible and practical. Colorectal screening may be in its infancy, but we know that it can improve mortality, and if this pilot shows that a national programme is truly feasible, then it should surely be embraced.
